Form 4: Teladoc Health Executive Arnnon Geshuri Reports Stock Transactions
SEC Form 4
Arnnon Geshuri, Chief People Officer of Teladoc Health, reports acquisition and disposal of common stock and derivative securities, including restricted stock units and performance stock units, in recent transactions.
Summary
- Arnnon Geshuri, the Chief People Officer of Teladoc Health, filed a Form 4 detailing changes in beneficial ownership.
- The report includes transactions from March 1, 2024, and March 4, 2024.
- Geshuri acquired shares through the vesting of restricted stock units (RSUs) and performance stock units (PSUs).
- Specifically, 1,179 RSUs and 11,470 RSUs converted to common stock on March 1, 2024.
- Additionally, 3,909 performance stock units converted to common stock on March 1, 2024.
- Geshuri also acquired 11,728 performance stock units based on the company's 2023 financial results.
- On March 4, 2024, Geshuri disposed of 6,108 shares at a price of $14.516 per share to cover tax withholding obligations related to the vesting of RSUs and PSUs.
- Following these transactions, Geshuri directly owns 38,470 shares of Teladoc Health common stock.
- Geshuri also holds 4,717 restricted stock units, 22,942 restricted stock units, 11,728 performance stock units, and 7,819 performance stock units.
Sentiment
Score: 5
Explanation: The sentiment is neutral as the filing primarily reflects routine transactions related to stock-based compensation. The sale of shares is for tax purposes, which is a common practice.
Positives
- The vesting of restricted stock units and performance stock units indicates that Geshuri is meeting certain performance criteria or time-based vesting schedules.
Negatives
- The sale of 6,108 shares, although for tax obligations, represents a disposal of shares by an insider.
Risks
- Insider selling, even for tax purposes, can sometimes be perceived negatively by the market.
Industry Context
Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders. These filings are closely watched by investors for signals about management's confidence in the company's prospects.
Comparison to Industry Standards
- Insider transactions are common across publicly traded companies, and the specifics of vesting schedules and tax-related sales are typical.
- Comparing Geshuri's transactions to those of other executives at similar telehealth companies (e.g., Amwell, Hims & Hers) would provide a better benchmark, but that data is not available in this document.
Stakeholder Impact
- The transactions could have a minor impact on shareholders due to the potential dilution from the vesting of stock units and the selling pressure from tax-related sales.
Key Dates
| Date | Description |
|---|---|
| 03/01/2022 | Grant date of 14,149 restricted stock units, vesting one-third on the first anniversary of the grant date, with the remainder vesting in eight substantially equal quarterly installments thereafter. |
| 03/03/2023 | Grant date of 34,412 restricted stock units, vesting one-third on March 1, 2024, with the remainder vesting in eight substantially equal quarterly installments thereafter. |
| 03/01/2024 | Vesting of restricted stock units and performance stock units; acquisition of performance stock units based on 2023 financial results. |
| 03/04/2024 | Sale of 6,108 shares to cover tax withholding obligations. |
| 03/05/2024 | Date of Form 4 signature. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.